Company: NCNA
Filing Date: 2025-04-04
Form Type: DRS
Source: 0000950123-25-003335
Chunk: 8

Company: NuCana plc
Filing Date: 2025-04-04
Form: DRS
Chunk 8
---
and NUC-3373. Corporate Information We were incorporated under the laws of England and Wales in 1997 under the name Biomed (UK) Limited, and commenced operations in 2008. On April 28, 2008, we changed our name to NuCana BioMed Limited. On August 29, 2017, we re-registeredas a public limited company and changed our name to NuCana plc. On October 2, 2017, we completed our initial public offering of ADSs on The Nasdaq Global Select Market. On November 9, 2023, we transferred our listing to The Nasdaq Capital Market. Our ADSs are traded under the symbol “NCNA”. Our registered office is located at 77/78 Cannon Street, London EC4N 6AF, United Kingdom. Our principal executive offices are located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom, our general telephone number is +44 (0)131 357 1111 and our internet address is https://www.nucana.com. Our website and the information contained on or accessible through our website are not part of this prospectus. Our agent for service of process in the United States is Corporation Service Company, 251 Little Falls Drive, Wilmington, DE 19808. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC (http://www.sec.gov). Implications of Being a Foreign Private Issuer We report under the Exchange Act as a non-U.S.company with foreign private issuer status. As long as we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:

| • |     | the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in 
 respect of a security registered under the Exchange Act;                                               |

| • |     | the sections of the Exchange Act requiring insiders to file public reports of their share ownership and   
 trading activities, and liability for insiders who profit from trades made in a short period of time; and |

| • |     | the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K upon the occurrence of specified significant events. |

2

Confidential Treatment Requested